The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

British Journal of Haematology

Volumn 136, Issue 4, 2007, Pages 624-627

  Giles, Francis J ^a,b   Borthakur, Gautam ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Thomas, Deborah ^a   Wierda, William ^a   Ferrajoli, Alessandra ^a   Kornblau, Steven ^a   Pierce, Sherry ^a   Albitar, Maher ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukaemia; Comorbidity; Induction chemotherapy; Prognosis

Indexed keywords

CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX SCORE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; EPIDEMIOLOGIC METHODS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846433493     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06476.x     Document Type: Article

References (12)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481-3485.
2. Burnett, A.K. & Mohite, U. (2006) Treatment of older patients with acute myeloid leukemia-new agents. Seminars in Hematology, 43, 96-106.
3. Charlson, M., Szatrowski, T.P., Peterson, J. & Gold, J. (1994) Validation of a combined comorbidity index. Journal of Clinical Epidemiology, 47, 1245-1251.
4. Frohling, S., Schlenk, R.F., Kayser, S., Morhardt, M., Benner, A., Dohner, K. & Dohner, H. (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, 108, 3280-3288.
5. Giles, F., Rizzieri, D., Karp, J., Vey, N., Ravandi, F., Faderl, S., Khan, K., Verhoef, G., Wijermans, P., Advani, A., Roboz, G., Kantarjian, H., Bilgrami, S., Ferrant, A., Daenen, S., Karsten, V., Cahill, A., Albitar, M., Mufti, G. & O'Brien, S. (2007) Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, has significant activity in patients aged 60 years or more with previously untreated acute myeloid leukemia. Journal of Clinical Oncology, 25, 25-31.
6. Gupta, V., Chun, K., Yi, Q.L., Minden, M., Schuh, A., Wells, R. & Brandwein, J. (2005) Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer, 103, 2082-2090.
7. Juliusson, G., Billstrom, R., Gruber, A., Hellstrom-Lindberg, E., Hoglunds, M., Karlsson, K., Stockelberg, D., Wahlin, A., Astrom, M., Arnesson, C., Brunell-Abrahamsson, U., Carstensen, J., Fredriksson, E., Holmberg, E., Nordenskjold, K. & Wiklund, F. (2006) Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia, 20, 42-47.
8. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J. & Estey, E. (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 106, 1090-1098.
9. Lang, K., Earle, C.C., Foster, T., Dixon, D., Van Gool, R. & Menzin, J. (2005) Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs and Aging, 22, 943-955.
10. Menzin, J., Lang, K., Earle, C.C., Kerney, D. & Mallick, R. (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine, 162, 1597-1603.
11. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
12. Wheatley, K., Brookes, C.L., Hills, R.K., Goldstone, A.H., Milligan, D.W., Prentice, A.G., Moorman, A.V. & Burnett, A.K. (2005) Prognostic factors in older AML patients receiving intensive and non-intensive therapy: analysis of the UK AML11 and AML14 Trials. Blood, 106, 674.